Issue of ballooning future medicine costs

Press Release – Doctors for the Protection of Health in Trade Agre Trade Minister puts up smoke screen on the real issue of ballooning future medicine costsTrade Minister puts up smoke screen on the real issue of ballooning future medicine costs “Minister Groser has once again avoided the real issue of the health costs of the TransPacific Partnership (TPPA) investment deal” says Dr Erik Monasterio, a specialist in psychiatry, speaking on behalf of Doctors for the Protection of Health in Trade Agreements. This weekend the Minister said that: “I don’t think you’re going to see anything dramatic (in terms of increased medicine prices) that’s going to flow through as a consequence of TPPA.” “Talking about dramatic changes in the price of today’s medicines avoids the problem entirely.” said Dr Monasterio. “One of the big issues is the price of the new medicines. All the new medicines from their original manufacturers are incredibly expensive and under the TPPA they would stay expensive for longer. For one particular new class of super-expensive drugs (known as biologics) the real question is the extra seven years that the United States drug manufacturers want us to wait before similar, less expensive versions(known as generics) are let into the country.“ For the seven most expensive biologics in New Zealand, every year of delay in getting virtually the same but less expensive versions would cost us...

Read More